The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study.
Int J Hematol
; 117(3): 366-377, 2023 Mar.
Article
in En
| MEDLINE
| ID: mdl-36427162
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Purpura, Thrombotic Thrombocytopenic
/
Single-Domain Antibodies
Type of study:
Prognostic_studies
Limits:
Adult
/
Humans
Language:
En
Journal:
Int J Hematol
Journal subject:
HEMATOLOGIA
Year:
2023
Document type:
Article
Affiliation country:
Japón